Tapewire

Nasdaq · USD

MIRM

Mirum Pharmaceuticals, Inc.

Export transactions ↓
Tapewire entity
2416
SEC CIK
0001759425
Parsed reports
352

Last 12 months

Inside the activity.

1 purchase rows · 59 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202501
Dec 202505
Jan 2026111
Feb 202604
Mar 202606
Apr 202601
May 202601
Jun 2026011
Jul 202609
Aug 202606
Sep 202604
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
May 10, 2024 Filed May 16, 2024 16:30 UTC
Vig PamelaCHIEF SCIENTIFIC OFFICER
GrantCommon Stock 94 $21.05 $1,978.32
Disclosure

SEC source: 0001415889-24-013354 · form4-05162024_040526.xml · nonDerivative · entry 1

Vig Pamela · CIK 0001780069 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,406

F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 94 shares by the Reporting Person on May 10, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
May 10, 2024 Filed May 16, 2024 20:30 UTC
Peetz ChristopherDirector · CHIEF EXECUTIVE OFFICER
GrantCommon Stock 817 $21.05 $17,194.58
Disclosure

SEC source: 0001415889-24-013355 · form4-05162024_040530.xml · nonDerivative · entry 1

Peetz Christopher · CIK 0001614740 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,770

F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 817 shares by the Reporting Person on May 10, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
May 10, 2024 Filed May 16, 2024 20:30 UTC
BJERKHOLT ERICCHIEF FINANCIAL OFFICER
GrantCommon Stock 470 $21.05 $9,891.62
Disclosure

SEC source: 0001415889-24-013356 · form4-05162024_040533.xml · nonDerivative · entry 1

BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,470

F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 470 shares by the Reporting Person on May 10, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
March 27, 2024 Filed Mar 28, 2024 00:47 UTC
BJERKHOLT ERICCHIEF FINANCIAL OFFICER
PurchaseCommon Stock 2,000 $24.80 $49,600.00
Disclosure

SEC source: 0001415889-24-009280 · form4-03282024_120312.xml · nonDerivative · entry 1

BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Read SEC document
March 25, 2024 Filed Mar 25, 2024 21:41 UTC
Radovich PeterPRESIDENT AND COO
SaleCommon Stock 4,303 $25.80 $111,017.40
Disclosure

SEC source: 0001415889-24-009046 · form4-03252024_090335.xml · nonDerivative · entry 1

Radovich Peter · CIK 0001650131 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,013

F1 · price: The weighted average sale price for the transaction reported was $25.80, and the range of prices were between $25.80 and $25.825. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
March 18, 2024 Filed Mar 18, 2024 21:34 UTC
BJERKHOLT ERICCHIEF FINANCIAL OFFICER
PurchaseCommon Stock 2,000 $25.80 $51,600.00
Disclosure

SEC source: 0001415889-24-008311 · form4-03182024_090313.xml · nonDerivative · entry 1

BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Read SEC document
February 02, 2024 Filed Feb 3, 2024 02:28 UTC
Howe JolandaSVP, GLOBAL CONTROLLER
SaleCommon Stock 735 $26.19 $19,250.97
Disclosure

SEC source: 0001415889-24-002412 · form4-02032024_020214.xml · nonDerivative · entry 2

Howe Jolanda · CIK 0001974200 · SVP, GLOBAL CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,759

F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
February 02, 2024 Filed Feb 5, 2024 21:12 UTC
Vig PamelaCHIEF SCIENTIFIC OFFICER
SaleCommon Stock 1,214 $26.19 $31,796.85
Disclosure

SEC source: 0001415889-24-002757 · form4-02062024_020209.xml · nonDerivative · entry 1

Vig Pamela · CIK 0001780069 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,691

F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
February 02, 2024 Filed Feb 6, 2024 02:10 UTC
Longpre LaraCHIEF DEVELOPMENT OFFICER
SaleCommon Stock 847 $26.19 $22,184.45
Disclosure

SEC source: 0001415889-24-002756 · form4-02062024_020236.xml · nonDerivative · entry 1

Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,407

F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
February 02, 2024 Filed Feb 6, 2024 02:05 UTC
Radovich PeterPRESIDENT AND COO
SaleCommon Stock 1,790 $26.19 $46,883.14
Disclosure

SEC source: 0001415889-24-002755 · form4-02062024_020222.xml · nonDerivative · entry 1

Radovich Peter · CIK 0001650131 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,695

F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
February 02, 2024 Filed Feb 6, 2024 02:04 UTC
Peetz ChristopherDirector · CHIEF EXECUTIVE OFFICER
SaleCommon Stock 6,013 $26.19 $157,491.29
Disclosure

SEC source: 0001415889-24-002754 · form4-02062024_020203.xml · nonDerivative · entry 1

Peetz Christopher · CIK 0001614740 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,112

F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
January 31, 2024 Filed Feb 3, 2024 02:28 UTC
Howe JolandaSVP, GLOBAL CONTROLLER
Exercise / conversionRestricted Stock Units · Derivative 1,772 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-002412 · form4-02032024_020214.xml · derivative · entry 3

Howe Jolanda · CIK 0001974200 · SVP, GLOBAL CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,543

Underlying: Common Stock · 1,772 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

F3 · derivative.exercise_date: The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024. 1,772 shares vested on January 31, 2024 ; 1,772 shares will vest January 31, 2025 and the remaining 1,771 shares will vest on January 31, 2026.

F3 · derivative.expiration_date: The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024. 1,772 shares vested on January 31, 2024 ; 1,772 shares will vest January 31, 2025 and the remaining 1,771 shares will vest on January 31, 2026.

Read SEC document
January 31, 2024 Filed Feb 3, 2024 02:28 UTC
Howe JolandaSVP, GLOBAL CONTROLLER
Exercise / conversionCommon Stock 1,772 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-002412 · form4-02032024_020214.xml · nonDerivative · entry 1

Howe Jolanda · CIK 0001974200 · SVP, GLOBAL CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,494

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
Howe JolandaSVP, GLOBAL CONTROLLER
GrantRestricted Stock Units · Derivative 4,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-001827 · form4-01252024_070108.xml · derivative · entry 2

Howe Jolanda · CIK 0001974200 · SVP, GLOBAL CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
Howe JolandaSVP, GLOBAL CONTROLLER
GrantStock Option (right to buy) · Derivative 18,000 $0.00 Strike: $26.49 $0.00
Disclosure

SEC source: 0001415889-24-001827 · form4-01252024_070108.xml · derivative · entry 1

Howe Jolanda · CIK 0001974200 · SVP, GLOBAL CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2034-01-22

F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 19:10 UTC
Vig PamelaCHIEF SCIENTIFIC OFFICER
GrantRestricted Stock Units · Derivative 8,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-001826 · form4-01252024_070108.xml · derivative · entry 2

Vig Pamela · CIK 0001780069 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 19:10 UTC
Vig PamelaCHIEF SCIENTIFIC OFFICER
GrantStock Option (right to buy) · Derivative 32,000 $0.00 Strike: $26.49 $0.00
Disclosure

SEC source: 0001415889-24-001826 · form4-01252024_070108.xml · derivative · entry 1

Vig Pamela · CIK 0001780069 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-01-22

F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
Longpre LaraCHIEF DEVELOPMENT OFFICER
GrantRestricted Stock Units · Derivative 8,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-001825 · form4-01252024_070106.xml · derivative · entry 2

Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
Longpre LaraCHIEF DEVELOPMENT OFFICER
GrantStock Option (right to buy) · Derivative 32,000 $0.00 Strike: $26.49 $0.00
Disclosure

SEC source: 0001415889-24-001825 · form4-01252024_070106.xml · derivative · entry 1

Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-01-22

F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
BJERKHOLT ERICCHIEF FINANCIAL OFFICER
GrantRestricted Stock Units · Derivative 8,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-001824 · form4-01252024_070104.xml · derivative · entry 2

BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
BJERKHOLT ERICCHIEF FINANCIAL OFFICER
GrantStock Option (right to buy) · Derivative 32,000 $0.00 Strike: $26.49 $0.00
Disclosure

SEC source: 0001415889-24-001824 · form4-01252024_070104.xml · derivative · entry 1

BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-01-22

F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
Radovich PeterPRESIDENT AND COO
GrantRestricted Stock Units · Derivative 17,250 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-001823 · form4-01252024_070101.xml · derivative · entry 2

Radovich Peter · CIK 0001650131 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,250

Underlying: Common Stock · 17,250 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
Radovich PeterPRESIDENT AND COO
GrantStock Option (right to buy) · Derivative 70,000 $0.00 Strike: $26.49 $0.00
Disclosure

SEC source: 0001415889-24-001823 · form4-01252024_070101.xml · derivative · entry 1

Radovich Peter · CIK 0001650131 · PRESIDENT AND COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2034-01-22

F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
Peetz ChristopherDirector · CHIEF EXECUTIVE OFFICER
GrantRestricted Stock Units · Derivative 37,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-001822 · form4-01252024_070102.xml · derivative · entry 2

Peetz Christopher · CIK 0001614740 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC
Peetz ChristopherDirector · CHIEF EXECUTIVE OFFICER
GrantStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $26.49 $0.00
Disclosure

SEC source: 0001415889-24-001822 · form4-01252024_070102.xml · derivative · entry 1

Peetz Christopher · CIK 0001614740 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-01-22

F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

Read SEC document
January 16, 2024 Filed Jan 19, 2024 00:42 UTC
Quan JoanneCHIEF MEDICAL OFFICER
GrantRestricted Stock Units · Derivative 37,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-001561 · form4-01192024_120106.xml · derivative · entry 2

Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 16, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 16, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Read SEC document
January 16, 2024 Filed Jan 19, 2024 00:42 UTC
Quan JoanneCHIEF MEDICAL OFFICER
GrantStock Option (right to buy) · Derivative 75,000 $0.00 Strike: $26.72 $0.00
Disclosure

SEC source: 0001415889-24-001561 · form4-01192024_120106.xml · derivative · entry 1

Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-01-15

F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest one year after January 16, 2024 (the "Vesting Commencement Date") and the balance of the shares will vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

Read SEC document
January 08, 2024 Filed Jan 10, 2024 01:09 UTC
Howe JolandaSVP, GLOBAL CONTROLLER
SaleCommon Stock 528 $28.04 $14,802.53
Disclosure

SEC source: 0001415889-24-000880 · form4-01102024_010137.xml · nonDerivative · entry 2

Howe Jolanda · CIK 0001974200 · SVP, GLOBAL CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 722

F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
January 08, 2024 Filed Jan 9, 2024 20:21 UTC
Vig PamelaHEAD OF RESEARCH & DEVELOPMENT
SaleCommon Stock 1,408 $28.03 $39,472.29
Disclosure

SEC source: 0001415889-24-000882 · form4-01102024_010110.xml · nonDerivative · entry 1

Vig Pamela · CIK 0001780069 · HEAD OF RESEARCH & DEVELOPMENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,905

F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
January 08, 2024 Filed Jan 10, 2024 01:28 UTC
Radovich PeterCHIEF OPERATING OFFICER
SaleCommon Stock 1,408 $28.03 $39,472.58
Disclosure

SEC source: 0001415889-24-000884 · form4-01102024_010106.xml · nonDerivative · entry 1

Radovich Peter · CIK 0001650131 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,485

F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
January 08, 2024 Filed Jan 10, 2024 01:25 UTC
Longpre LaraCHIEF DEVELOPMENT OFFICER
SaleCommon Stock 1,019 $28.04 $28,567.67
Disclosure

SEC source: 0001415889-24-000883 · form4-01102024_010122.xml · nonDerivative · entry 1

Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,254

F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
January 08, 2024 Filed Jan 10, 2024 01:12 UTC
Peetz ChristopherDirector · PRESIDENT AND CEO
SaleCommon Stock 5,209 $28.03 $146,033.27
Disclosure

SEC source: 0001415889-24-000881 · form4-01102024_010133.xml · nonDerivative · entry 1

Peetz Christopher · CIK 0001614740 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,125

F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
January 06, 2024 Filed Jan 10, 2024 01:09 UTC
Howe JolandaSVP, GLOBAL CONTROLLER
Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-000880 · form4-01102024_010137.xml · derivative · entry 3

Howe Jolanda · CIK 0001974200 · SVP, GLOBAL CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

F3 · derivative.exercise_date: The restricted stock units vest in a series of three successive equal annual installments beginning January 6, 2023. 1,250 shares vested on each of January 6, 2023 and January 6, 2024 and the remaining 1,250 shares will vest on January 6, 2025.

F3 · derivative.expiration_date: The restricted stock units vest in a series of three successive equal annual installments beginning January 6, 2023. 1,250 shares vested on each of January 6, 2023 and January 6, 2024 and the remaining 1,250 shares will vest on January 6, 2025.

Read SEC document
January 06, 2024 Filed Jan 10, 2024 01:09 UTC
Howe JolandaSVP, GLOBAL CONTROLLER
Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-000880 · form4-01102024_010137.xml · nonDerivative · entry 1

Howe Jolanda · CIK 0001974200 · SVP, GLOBAL CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

Read SEC document
December 05, 2023 Filed Dec 6, 2023 22:16 UTC
Howe JolandaSVP, Global Controller
Exercise / conversionStock Option (right to buy) · Derivative 2,500 $0.00 Strike: $2.94 $0.00
Disclosure

SEC source: 0001209191-23-057650 · doc4.xml · derivative · entry 3

Howe Jolanda · CIK 0001974200 · SVP, Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,400

Underlying: Common Stock · 2,500 shares

Expires 2029-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 1/4th of the 62,500 shares originally subject to the option vested one year after February 28, 2019, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter.

Read SEC document
December 05, 2023 Filed Dec 6, 2023 22:16 UTC
Howe JolandaSVP, Global Controller
SaleCommon Stock 2,500 $32.40 $81,000.00
Disclosure

SEC source: 0001209191-23-057650 · doc4.xml · nonDerivative · entry 2

Howe Jolanda · CIK 0001974200 · SVP, Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Read SEC document
December 05, 2023 Filed Dec 6, 2023 22:16 UTC
Howe JolandaSVP, Global Controller
Exercise / conversionCommon Stock 2,500 $2.94 $7,350.00
Disclosure

SEC source: 0001209191-23-057650 · doc4.xml · nonDerivative · entry 1

Howe Jolanda · CIK 0001974200 · SVP, Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 10, 2023 Filed Nov 15, 2023 20:14 UTC
Vig PamelaHead of Research & Development
GrantCommon Stock 527 $22.29 $11,745.25
Disclosure

SEC source: 0001209191-23-055436 · doc4.xml · nonDerivative · entry 1

Vig Pamela · CIK 0001780069 · Head of Research & Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,313

F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 527 shares by the Reporting Person on November 10, 2023 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
November 10, 2023 Filed Nov 16, 2023 01:13 UTC
Longpre LaraChief Development Officer
GrantCommon Stock 434 $22.29 $9,672.56
Disclosure

SEC source: 0001209191-23-055434 · doc4.xml · nonDerivative · entry 1

Longpre Lara · CIK 0001780347 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,273

F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 434 shares by the Reporting Person on November 10, 2023 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
November 10, 2023 Filed Nov 16, 2023 01:11 UTC
Radovich PeterChief Operating Officer
GrantCommon Stock 218 $22.29 $4,858.57
Disclosure

SEC source: 0001209191-23-055433 · doc4.xml · nonDerivative · entry 1

Radovich Peter · CIK 0001650131 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,893

F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 218 shares by the Reporting Person on November 10, 2023 pursuant to the Issuer's Employee Stock Purchase Plan.

Read SEC document
November 09, 2023 Filed Nov 14, 2023 21:35 UTC PurchaseCommon Stock 2,910 $28.30 $82,353.00
Disclosure

SEC source: 0001209191-23-055180 · doc4.xml · nonDerivative · entry 1

Heron Patrick J · CIK 0001365617 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 161,963

F1 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

Read SEC document
September 14, 2023 Filed Sep 14, 2023 23:33 UTC Exercise / conversionStock Option (right to buy) · Derivative 14,216 $0.00 Strike: $2.94 $0.00
Disclosure

SEC source: 0001209191-23-049511 · doc4.xml · derivative · entry 8

GREY MICHAEL G · CIK 0001240122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,176

Underlying: Common Stock · 14,216 shares

Expires 2029-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4th of the shares vest one year after November 5, 2018, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

Read SEC document
September 14, 2023 Filed Sep 14, 2023 23:33 UTC SaleCommon Stock 14,216 $32.00 $454,912.00
Disclosure

SEC source: 0001209191-23-049511 · doc4.xml · nonDerivative · entry 4

GREY MICHAEL G · CIK 0001240122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 30, 2022.

Read SEC document
September 14, 2023 Filed Sep 14, 2023 23:33 UTC Exercise / conversionCommon Stock 14,216 $2.94 $41,738.18
Disclosure

SEC source: 0001209191-23-049511 · doc4.xml · nonDerivative · entry 3

GREY MICHAEL G · CIK 0001240122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 13, 2023 Filed Sep 14, 2023 23:33 UTC Exercise / conversionStock Option (right to buy) · Derivative 392 $0.00 Strike: $2.94 $0.00
Disclosure

SEC source: 0001209191-23-049511 · doc4.xml · derivative · entry 7

GREY MICHAEL G · CIK 0001240122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,392

Underlying: Common Stock · 392 shares

Expires 2029-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4th of the shares vest one year after November 5, 2018, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

Read SEC document
September 13, 2023 Filed Sep 14, 2023 23:33 UTC SaleCommon Stock 392 $32.00 $12,544.00
Disclosure

SEC source: 0001209191-23-049511 · doc4.xml · nonDerivative · entry 2

GREY MICHAEL G · CIK 0001240122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 30, 2022.

Read SEC document
September 13, 2023 Filed Sep 14, 2023 23:33 UTC Exercise / conversionCommon Stock 392 $2.94 $1,150.91
Disclosure

SEC source: 0001209191-23-049511 · doc4.xml · nonDerivative · entry 1

GREY MICHAEL G · CIK 0001240122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 392

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 13, 2023 Filed Sep 15, 2023 20:56 UTC PurchaseCommon Stock 2,625 $31.02 $81,424.88
Disclosure

SEC source: 0001209191-23-049614 · doc4.xml · nonDerivative · entry 1

Heron Patrick J · CIK 0001365617 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 159,053

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.9633 to $31.0499, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

Read SEC document
September 12, 2023 Filed Sep 13, 2023 20:39 UTC PurchaseCommon Stock 3,750 $30.60 $114,763.88
Disclosure

SEC source: 0001209191-23-049292 · doc4.xml · nonDerivative · entry 2

Heron Patrick J · CIK 0001365617 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 156,428

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.2781 to $30.7970, inclusive.

F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

Read SEC document
September 11, 2023 Filed Sep 12, 2023 22:23 UTC
BJERKHOLT ERICChief Financial Officer
GrantRestricted Stock Units · Derivative 55,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-049133 · doc4.xml · derivative · entry 3

BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one year anniversary of September 11, 2023.

F4 · derivative.expiration_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one year anniversary of September 11, 2023.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.